Poor
Not Aligned
Patient Risk:
High
Summary
Poor alignment: many key dosing/administration, pediatric, and route-specific claims are unsupported/absent from the provided label text, and the response omits or does not address multiple critical FDA label safety sections (contraindications/warnings/interactions/specific populations/dosing details).
Category Scores
Accurate Statements
Erythromycin works by inhibiting bacterial protein synthesis.
Microbiology (acts by inhibition of protein synthesis by binding 50S ribosomal subunits).
Erythromycin binds to the 50S ribosomal subunit of bacteria.
Microbiology (binding 50S ribosomal subunits).
Common side effects of erythromycin include nausea, vomiting, abdominal pain, and diarrhea.
Adverse Reactions (nausea, vomiting, abdominal pain, diarrhea listed as most frequent GI side effects).
There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency and in patients receiving high doses of erythromycin.
Adverse Reactions (reversible hearing loss; chiefly renal insufficiency and high doses).
Unsupported Statements
Typical oral adult dosages of erythromycin range from 250 mg to 1 gram every six to eight hours.
No adult oral dosing regimen is present in the provided label excerpts (DOSAGE AND ADMINISTRATION text provided contains only fasting-state timing).
For severe infections, the oral erythromycin dose may be increased.
No dose-adjustment guidance is present in the provided label excerpts.
Typical intravenous adult erythromycin dosing is 250 mg to 1 gram every six hours.
No intravenous adult dosing regimen is present in the provided label excerpts.
For critical cases, intravenous erythromycin may be increased to 1 gram every four hours.
No intravenous dose escalation regimen is present in the provided label excerpts.
Topical erythromycin formulations for skin conditions typically involve applying the medication two to three times daily.
The provided label excerpts do not include topical dosing frequency or topical formulation directions.
Pediatric erythromycin dosages are calculated based on body weight.
The provided label excerpts do not contain pediatric dosing instructions.
Pediatric erythromycin dosing generally ranges from 30 to 50 mg per kilogram of body weight per day, divided into multiple doses.
No pediatric mg/kg/day dosing ranges are present in the provided label excerpts.
In severe pediatric cases, the erythromycin dose can be increased to 100 mg per kilogram per day.
No pediatric maximum dose escalation information is present in the provided label excerpts.
For intravenous use in children, the recommended erythromycin dose is 15 to 20 mg per kilogram per day.
No pediatric IV mg/kg/day dosing is present in the provided label excerpts.
Pediatric intravenous erythromycin dosing is divided into doses administered every six hours.
No pediatric IV dosing interval is present in the provided label excerpts.
Erythromycin is available in oral capsules, tablets, and liquid suspensions.
The provided label excerpts do not list dosage forms for this specific product.
Erythromycin topical preparations (ointments and gels) are used for skin conditions.
The provided label excerpts do not describe topical ointment/gel use; they only mention skin/skin structure infections generally in indications, without topical product form/frequency.
Erythromycin ophthalmic ointments are available for eye infections.
The provided label excerpts mention conjunctivitis of the newborn as an indication, but do not describe ophthalmic ointment formulation availability/usage.
The duration of erythromycin treatment varies depending on infection type and severity.
No treatment duration variability or regimen-length guidance is present in the provided label excerpts.
Commonly, erythromycin treatment courses range from 7 to 14 days.
No course duration ranges are present in the provided label excerpts.
Some infections may require shorter or longer durations determined by a healthcare professional.
No duration guidance is present in the provided label excerpts.
Erythromycin is a macrolide antibiotic.
No antibiotic class description is present in the provided label excerpts.
Erythromycin prevents the translocation step in protein elongation.
The provided Microbiology section does not mention the translocation step.
Erythromycin stops bacteria from growing and multiplying.
The provided Microbiology section describes inhibition of protein synthesis, not growth/multiplication wording.
Azithromycin is an alternative antibiotic to erythromycin for treating bacterial infections.
No comparative/alternative antibiotic class guidance is present in the provided label excerpts.
Clarithromycin is an alternative antibiotic to erythromycin for treating bacterial infections.
No comparative/alternative antibiotic guidance is present in the provided label excerpts.
Other macrolide antibiotics can be alternatives to erythromycin.
No comparative/alternative antibiotic guidance is present in the provided label excerpts.
Penicillins are alternative antibiotic classes to erythromycin for treating bacterial infections.
No comparative/alternative antibiotic guidance is present in the provided label excerpts.
Cephalosporins are alternative antibiotic classes to erythromycin for treating bacterial infections.
No comparative/alternative antibiotic guidance is present in the provided label excerpts.
Tetracyclines are alternative antibiotic classes to erythromycin for treating bacterial infections.
While the indications mention tetracyclines contraindicated/not tolerated for specific infections, the response frames this as a general alternative class statement not clearly supported as written in the provided excerpts.
Erythromycin itself is a well-established antibiotic with patent protection that expired many years ago.
No patent or intellectual property information is present in the provided label excerpts.
Specific formulations or combination products containing erythromycin might have independent patent protection.
No patent or intellectual property information is present in the provided label excerpts.
Contradictions
Important Omissions
Contraindications section content (not addressed).
Importance:
High
Boxed warning(s) (not addressed).
Importance:
High
Warnings and precautions, including QT prolongation/arrhythmias and pseudomembranous colitis warning content (not addressed explicitly).
Importance:
High
Drug interactions (e.g., theophylline, digoxin, oral anticoagulants; CYP3A-related interactions) (not addressed).
Importance:
High
Use in specific populations, including pregnancy/lactation-related information (not addressed).
Importance:
High
Pediatric use dosing/safety details and administration specifics (not addressed; pediatric section only cross-references other sections in provided text).
Importance:
High
Actual dosage and administration instructions for this product (provided label excerpt only provides fasting-state timing; regimen details claimed by the AI are not supported).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The AI response includes multiple specific adult and pediatric dosing/route regimen claims that are not supported by the provided label excerpts, and it omits critical label sections covering contraindications/warnings/precautions/interactions/specific populations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major dosing/administration and pediatric regimen claims are unsupported/absent from the provided label excerpts, plus critical safety labeling coverage is missing.
Suggested Improvement
Remove or revise all specific oral/IV/pediatric dose and interval ranges and topical/ophthalmic formulation/frequency statements unless directly supported by the provided FDA label text; include and accurately reflect label-required safety sections (contraindications, warnings/precautions, drug interactions, and specific population guidance).